Dynavax Technologies Corp. signed a deal with GlaxoSmithKline plc to develop endosomal toll-like receptor (TLR) inhibitors targeting immunoinflammatory diseases, which could potentially be worth more than $810 million for the Berkeley, Calif.-based biotech.